Toll Free: 1-888-928-9744
Published: Dec, 2014 | Pages:
29 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Cleveland BioLabs, Inc. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Cleveland BioLabs, Inc. - Product Pipeline Review - 2014', provides an overview of the Cleveland BioLabs, Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Cleveland BioLabs, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Cleveland BioLabs, Inc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Cleveland BioLabs, Inc.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Cleveland BioLabs, Inc.'s pipeline products Reasons to buy - Evaluate Cleveland BioLabs, Inc.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Cleveland BioLabs, Inc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Cleveland BioLabs, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Cleveland BioLabs, Inc. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Cleveland BioLabs, Inc. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Cleveland BioLabs, Inc. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 3 List of Figures 3 Cleveland BioLabs, Inc. Snapshot 4 Cleveland BioLabs, Inc. Overview 4 Key Information 4 Key Facts 4 Cleveland BioLabs, Inc. - Research and Development Overview 5 Key Therapeutic Areas 5 Cleveland BioLabs, Inc. - Pipeline Review 7 Pipeline Products by Stage of Development 7 Pipeline Products - Monotherapy 8 Cleveland BioLabs, Inc. - Pipeline Products Glance 9 Cleveland BioLabs, Inc. - Late Stage Pipeline Products 9 Phase III Products/Combination Treatment Modalities 9 Cleveland BioLabs, Inc. - Clinical Stage Pipeline Products 10 Phase I Products/Combination Treatment Modalities 10 Cleveland BioLabs, Inc. - Early Stage Pipeline Products 11 Preclinical Products/Combination Treatment Modalities 11 Cleveland BioLabs, Inc. - Drug Profiles 12 entolimod 12 Product Description 12 Mechanism of Action 12 R&D Progress 12 CBLB-612 14 Product Description 14 Mechanism of Action 14 R&D Progress 14 CBLB-613 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 M-606 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 Cleveland BioLabs, Inc. - Pipeline Analysis 18 Cleveland BioLabs, Inc. - Pipeline Products by Target 18 Cleveland BioLabs, Inc. - Pipeline Products by Route of Administration 19 Cleveland BioLabs, Inc. - Pipeline Products by Molecule Type 20 Cleveland BioLabs, Inc. - Pipeline Products by Mechanism of Action 21 Cleveland BioLabs, Inc. - Recent Pipeline Updates 22 Cleveland BioLabs, Inc. - Dormant Projects 26 Cleveland BioLabs, Inc. - Locations And Subsidiaries 27 Head Office 27 Other Locations & Subsidiaries 27 Appendix 28 Methodology 28 Coverage 28 Secondary Research 28 Primary Research 28 Expert Panel Validation 28 Contact Us 29 Disclaimer 29
List of Tables Cleveland BioLabs, Inc., Key Information 4 Cleveland BioLabs, Inc., Key Facts 4 Cleveland BioLabs, Inc. - Pipeline by Indication, 2014 6 Cleveland BioLabs, Inc. - Pipeline by Stage of Development, 2014 7 Cleveland BioLabs, Inc. - Monotherapy Products in Pipeline, 2014 8 Cleveland BioLabs, Inc. - Phase III, 2014 9 Cleveland BioLabs, Inc. - Phase I, 2014 10 Cleveland BioLabs, Inc. - Preclinical, 2014 11 Cleveland BioLabs, Inc. - Pipeline by Target, 2014 18 Cleveland BioLabs, Inc. - Pipeline by Route of Administration, 2014 19 Cleveland BioLabs, Inc. - Pipeline by Molecule Type, 2014 20 Cleveland BioLabs, Inc. - Pipeline Products by Mechanism of Action, 2014 21 Cleveland BioLabs, Inc. - Recent Pipeline Updates, 2014 22 Cleveland BioLabs, Inc. - Dormant Developmental Projects,2014 26 Cleveland BioLabs, Inc., Subsidiaries 27
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.